A cloned frog vasoactive intestinal polypeptide pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC(1) and VPAC(2) receptors in mammals
D. Alexandre et al., A cloned frog vasoactive intestinal polypeptide pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC(1) and VPAC(2) receptors in mammals, ENDOCRINOL, 140(3), 1999, pp. 1285-1293
Three receptor subtypes for the neuropeptides vasoactive intestinal peptide
(VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) have
been identified in mammals: the PAC(1) receptor (PAC(1)-R) which is selecti
vely activated by PACAP, and two VPAC receptors (VPAC(1)-R and VPAC(2)-R),
which are equally stimulated by PACAP and VIP. The structures of PACAP and
VIP have been well conserved during evolution, but little is known about VI
P/PACAP receptors in nonmammalian species. An amphibian VTP/PACAP receptor
complementary DNA (cDNA) has been cloned and characterized from a frog (Ran
a ridibunda) pituitary cDNA library. The predicted protein contains seven p
utative transmembrane domains and exhibits the highest sequence identity (6
5%) with the human VPAC(1)-R. The cloned cDNA was transiently expressed in
LLC-PK1 cells, and its pharmacological profile was determined in comparison
with the human VPAC(1)-R. Both PACAP and VIP stimulated cAMP accumulation
through the cloned receptor with an EC50 of about 30 nM. In contrast, secre
tin, at concentrations that stimulate the human VPAC(1)-R, had no effect on
cAMP production. RT-PCR analysis revealed the widespread distribution of t
his frog VIP/PACAP receptor in peripheral tissues. In situ hybridization hi
stochemistry using a complementary RNA probe showed that the receptor gene
is highly expressed in several hypothalamic and thalamic nuclei and to a le
sser extent, in the pallium and striatum. In the pituitary, the highest mes
senger RNA levels were detected in the distal lobe. Taken together, these d
ata show that the cloned frog receptor shares several common features with
both the VPAC(1)-R and VPAC(2)-R of mammals; the frog receptor exhibits the
highest sequence identity with mammalian VPAC(1)-R, but the lack of effect
of secretin and the brain distribution of the receptor are reminiscent of
the characteristics of the mammalian VPAC(2)-R. The sequence of the frog re
ceptor should thus prove useful to decipher the structure-activity relation
ships of the VIP/PACAP receptor family.